A Phase 2 interventional study of Gemcitabine and avastin in Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-07.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing gemcitabine in Colorectal Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Gemcitabine · Colorectal Neoplasms.
Among the 19 studies testing gemcitabine in Colorectal Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2003, is one of 12 in phase 2, and was the 7th registered.
6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 19 studies testing gemcitabine in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15
First in 1997; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 49 across the 19 interventional studies. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 19 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
37 studies in Colorectal Neoplasms by Eli Lilly and Company: 4 open now, 7 under way, none of them phase 3. Of 29 finished, 15 (52%) have results posted.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2003, is one of 16 in phase 2, and was the 9th registered.
Eli Lilly and Company’s Colorectal Neoplasms studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing gemcitabine in Colorectal Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 37 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease after they receive treatment, and how long the response they get from the treatment lasts. The amount and type of side effects/toxicities of each regimen will also be evaluated. The regimen including Oxaliplatin + 5FU/Folinic Acid is a current standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid
Drug: Gemcitabine · Drug: avastin · Drug: 5FU/folinic acid
Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid
Drug: avastin · Drug: 5FU/folinic acid · Drug: oxaliplatin
900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
Also known as: Gemzar
5 milligrams per kilogram (mg/kg)
Drug pages: Fluorouracil · Leucovorin
Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG). Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4). 5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).
85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Time to Progressive Disease
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
Time frame: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Progression-Free Survival
Defined as the time from randomization to the first observation of disease progression, or death due to any cause.
Time frame: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Tumor Response - Avastin Subgroup
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Time to Progressive Disease - Avastin Subgroup
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
Time frame: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Progression-Free Survival - Avastin Subgroup
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
Time frame: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Survival at 12 Months and 24 Months - Avastin Subgroup
Percentage of participants who were alive at 12 months and 24 months.
Time frame: randomization to the date of death from any cause (up to 24 months)
Toxicity - Avastin Subgroup
Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either \>=1 Grade 4 or \>=2 Grade 3 adverse events
Time frame: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Duration of Response - A+FOLFOX4 - Avastin Subgroup
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Milestone | A+FFG | A + FOLFOX 4 |
|---|---|---|
| Started | 42 | 42 |
| Completed | 3 | 23 |
| Not completed | 39 | 19 |
| Withdrew: Disease progression | 23 | 6 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Withdrawal by subject | 5 | 5 |
| Withdrew: Patient non-compliance | 0 | 1 |
| Withdrew: Unacceptable toxicity exhibited by drug | 2 | 1 |
| Withdrew: Other | 5 | 2 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | A+FFG | A + FOLFOX 4 |
|---|---|---|
| Complete Response (CR) | 1 | 2 |
| Partial Response (PR) | 3 | 15 |
| Overall Response Rate (CR+PR) | 4 | 17 |
| Stable Disease (SD) | 21 | 16 |
| Disease Control Rate (CR+PR+SD) | 25 | 33 |
| Progressive Disease | 14 | 7 |
| Unknown | 3 | 2 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
| months | A+FFG | A + FOLFOX 4 |
|---|---|---|
| Time to Progressive Disease | 8.6 (5.3 to 17.9) | 9.7 (7.3 to 11.2) |
Defined as the time from randomization to the first observation of disease progression, or death due to any cause.
| months | A+FFG | A + FOLFOX 4 |
|---|---|---|
| Progression-Free Survival | 8.6 (4.7 to 17.9) | 9.5 (6.9 to 11.2) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| months | A+FFG | A + FOLFOX 4 |
|---|---|---|
| Overall Survival | 20.6 (14.8 to 26.7) | 19.7 (11.2 to 32.0) |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | A+FFG - Avastin Subgroup | A + FOLFOX 4 - Avastin Subgroup |
|---|---|---|
| Complete Response (CR) | 0 | 1 |
| Partial Response (PR) | 0 | 8 |
| Overall Response Rate (CR+PR) | 0 | 9 |
| Stable Disease (SD) | 11 | 8 |
| Disease Control Rate (CR+PR+SD) | 11 | 17 |
| Progressive Disease | 6 | 1 |
| Unknown | 1 | 0 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
| months | A+FFG - Avastin Subgroup | A + FOLFOX 4 - Avastin Subgroup |
|---|---|---|
| Time to Progressive Disease - Avastin Subgroup | 13.7 (4.6 to 19.3) | 13.8 (6.3 to 23.7) |
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
| months | A+FFG - Avastin Subgroup | A + FOLFOX 4 - Avastin Subgroup |
|---|---|---|
| Progression-Free Survival - Avastin Subgroup | 13.7 (4.6 to 19.3) | 11.5 (6.3 to 18.1) |
Percentage of participants who were alive at 12 months and 24 months.
| percentage of participants alive | A+FFG - Avastin Subgroup | A + FOLFOX 4 - Avastin Subgroup |
|---|---|---|
| 12-Month Survival | 75.6 (47.3 to 90.1) | 83.3 (56.8 to 94.3) |
| 24-Month Survival | 50.4 (24.9 to 71.4) | 66.7 (40.4 to 83.4) |
Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either \>=1 Grade 4 or \>=2 Grade 3 adverse events
| participants | A+FFG - Avastin Subgrouup | A + FOLFOX 4 - Avastin Subgroup |
|---|---|---|
| Neutropenia (Grade 3) | 3 | 5 |
| Neutropenia (Grade 4) | 5 | 1 |
| Thrombocytopenia (Grade 3) | 1 | 0 |
| Thrombocytopenia (Grade 4) | 0 | 0 |
| Leukopenia (Grade 3) | 3 | 0 |
| Leukopenia (Grade 4) | 1 | 0 |
| Anemia (Grade 3) | 0 | 0 |
| Anemia (Grade 4) | 0 | 0 |
| Febrile neutropenia (Grade 3) | 0 | 1 |
| Febrile neutropenia (Grade 4) | 0 | 0 |
| Diarrhea (Grade 3) | 1 | 0 |
| Diarrhea (Grade 4) | 0 | 1 |
| Small intestinal obstruction (Grade 3) | 1 | 1 |
| Small intestinal obstruction (Grade 4) | 0 | 0 |
| Fatigue (Grade 3) | 0 | 2 |
| Fatigue (Grade 4) | 0 | 0 |
| Cerebral infarction (Grade 3) | 0 | 0 |
| Cerebral infarction (Grade 4) | 0 | 0 |
| Hyperglycemia (Grade 3) | 0 | 0 |
| Hyperglycemia (Grade 4) | 0 | 0 |
| Dehydration (Grade 3) | 0 | 1 |
| Dehydration (Grade 4) | 0 | 0 |
| Deep vein thrombosis (Grade 3) | 0 | 2 |
| Deep vein thrombosis (Grade 4) | 0 | 0 |
| Myocardial infarction (Grade 3) | 0 | 0 |
| Myocardial infarction (Grade 4) | 0 | 2 |
| Subdural hematoma (Grade 3) | 0 | 0 |
| Subdural hematoma (Grade 4) | 0 | 0 |
| Perirectal abscess (Grade 3) | 1 | 0 |
| Perirectal abscess (Grade 4) | 0 | 0 |
| Hypoxia (Grade 3) | 0 | 0 |
| Hypoxia (Grade 4) | 0 | 0 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | A+FFG | A + FOLFOX 4 |
|---|---|---|
| Duration of Response | 12.7 (5.5 to 32.9) | 7.9 (4.4 to 9.8) |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | A + FOLFOX 4 - Avastin Subgroup |
|---|---|
| Duration of Response - A+FOLFOX4 - Avastin Subgroup | 5.2 (4.2 to 13.8) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A+FFG | — | 11/42 (26.2%) | 40/42 (95.2%) |
| A + FOLFOX 4 | — | 8/42 (19%) | 41/42 (97.6%) |
| Event | A+FFG | A + FOLFOX 4 |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/42 | 2/42 |
| Myocardial infarctionCardiac disorders | 0/42 | 2/42 |
| Small intestinal obstructionGastrointestinal disorders | 1/42 | 2/42 |
| Urinary tract infectionInfections and infestations | 0/42 | 2/42 |
| PalpitationsCardiac disorders | 1/42 | 0/42 |
| ConstipationGastrointestinal disorders | 0/42 | 1/42 |
| DiarrhoeaGastrointestinal disorders | 1/42 | 1/42 |
| EnteritisGastrointestinal disorders | 1/42 | 0/42 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/42 | 1/42 |
| Perirectal abscessGastrointestinal disorders | 1/42 | 1/42 |
| Event | A+FFG | A + FOLFOX 4 |
|---|---|---|
| NauseaGastrointestinal disorders | 19/42 | 25/42 |
| NeutropeniaBlood and lymphatic system disorders | 24/42 | 16/42 |
| FatigueGeneral disorders | 22/42 | 24/42 |
| DiarrhoeaGastrointestinal disorders | 15/42 | 17/42 |
| AnaemiaBlood and lymphatic system disorders | 16/42 | 4/42 |
| ConstipationGastrointestinal disorders | 15/42 | 10/42 |
| VomitingGastrointestinal disorders | 8/42 | 15/42 |
| ThrombocytopeniaBlood and lymphatic system disorders | 14/42 | 8/42 |
| ParaesthesiaNervous system disorders | 2/42 | 11/42 |
| PyrexiaGeneral disorders | 10/42 | 6/42 |
| Age Continuous(years) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| Median | 62 (28 to 79) | 64 (32 to 81) | 63 (28 to 81) |
| Sex: Female, Male(Participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| Female | 21 | 22 | 43 |
| Male | 21 | 20 | 41 |
| Region of Enrollment(participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| United States | 42 | 42 | 84 |
| Diagnosis to Enrollment(participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| <6 months | 29 | 29 | 58 |
| >=6 months | 13 | 13 | 26 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| 0 - Fully Active | 23 | 20 | 43 |
| 1 - Ambulatory, Restricted Strenuous Activity | 19 | 22 | 41 |
| Primary Tumor Site(participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| Colon | 25 | 35 | 60 |
| Rectum | 10 | 4 | 14 |
| Other | 7 | 3 | 10 |
| Prior Adjuvant Therapy(participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| Yes | 12 | 14 | 26 |
| No | 30 | 28 | 58 |
| Race/Ethnicity(participants) | A+FFG | A + FOLFOX 4 | Total |
|---|---|---|---|
| Caucasian | 33 | 34 | 67 |
| African descent | 5 | 6 | 11 |
| Asian | 0 | 1 | 1 |
| Hispanic | 4 | 1 | 5 |
2 further baseline measures are reported on the registry.
The record gives a start of Jun 2003 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine